The Board of Directors of Becton, Dickinson & Co. has authorized the company's management to begin spinning off the diabetes business into a separate public company, NewCo. Its shares are planned to be distributed to BD shareholders. The spin-off is expected to be completed in the 2nd half of 2022.
The Board of Directors of Becton, Dickinson & Co. has authorized the company's management to begin spinning off the diabetes business into a separate public company, NewCo. Its shares are planned to be distributed to BD shareholders. The spin-off is expected to be completed in the 2nd half of 2022. 
investors.bd.com
English (US) 